Patient Frequently Asked Questions


Thank you for visiting the STAMPEDE website. The trial team are not able to provide medical advice to patients or relatives who contact us. If you have questions about prostate cancer or the STAMPEDE trial please talk to your cancer doctor or cancer specialist nurse. If you would like to talk to someone other than your medical team you can use the following link for advice from the Prostate Cancer UK team:


Please check out the 'About' sections of the patients tab for more information or speak to your clinician and nursing staff for more information.


What is the MRC CTU and what does it do?


How will patient's personal information be used?

The STAMPEDE study aims to test if different ways of treating prostate cancer can improve disease control, reduce relapse and improve life expectancy. The Medical Research Council is the sponsor for this study, based in the United Kingdom. University College London (UCL), through the MRC Clinical Trial Centre at UCL, will be using information from patients and patient medical records in order to undertake this study and will act as data controller for this study. UCL will be responsible for looking after patients’ information and using it properly. UCL will keep identifiable information about patients for 25 years after the study has finished.

Patients’ rights to access, change or move their information is limited, as we need to manage their information in specific ways in order for the research to be reliable and accurate. If they withdraw from the study, we will keep the information about them that we have already obtained. To safeguard their rights, we will use the minimum personally – identifiable information possible.

You can find out more about how we use patients’ information at

Their sites will collect information from patients and patient medical records for this research study in accordance with our instructions.

The patients’ hospitals will use their names, NHS numbers and contact details to contact them about the research study, and make sure that relevant information about the study is recorded for their care, and to oversee the quality of the study. Individuals from UCL and regulatory organisations may look at their medical and research records to check the accuracy of the research study. The patients’ hospital will pass their names, postcodes and NHS numbers to UCL along with the information collected from them and their medical records. The people who analyse the information will not be able to identify them and will not be able to find out their names, NHS numbers or contact details.

Their hospitals will keep identifiable information about them from this study for at least 25 years after the study has finished.

UCL will collect information about patients, for research, from their hospital sites, NHS Digital, Public Health England (PHE,) and the National Cancer Registration and Analysis Service (NCRAS). This information will include their names, postcodes and NHS numbers and health information. This health information is regarded as a special category of information as defined by the General Data Protection Regulation (GDPR). We will use this information to track patients’ long term health status (

Where information could identify patients, the information will be held securely with strict arrangements about who can access the information.


Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.